APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Hodgkin's Lymphoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Non-Hodgkin's Lymphoma Drug Market Analysis and Forecast 2026-2032

2 January 2026198 pages

Choose your research edition.

Industry ResearchNon-Hodgkin's Lymphoma Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Hodgkin's Lymphoma Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Non-Hodgkin's Lymphoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Hodgkin's Lymphoma Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-Hodgkin's Lymphoma Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Non-Hodgkin's Lymphoma Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Non-Hodgkin's Lymphoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Non-Hodgkin's Lymphoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Non-Hodgkin's Lymphoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Non-Hodgkin's Lymphoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Non-Hodgkin's Lymphoma Drug include Acrotech Biopharma, Eagle Pharmaceuticals, Epizyme, Gilead Sciences, MundiPharma, Secura Bio, TG Therapeutics, Bayer and Roche, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Non-Hodgkin's Lymphoma Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Non-Hodgkin's Lymphoma Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Non-Hodgkin's Lymphoma Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non-Hodgkin's Lymphoma Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Non-Hodgkin's Lymphoma Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Non-Hodgkin's Lymphoma Drug revenue, projected growth trends, production technology, application and end-user industry.

Non-Hodgkin's Lymphoma Drug Segment by Company

Acrotech Biopharma

Eagle Pharmaceuticals

Epizyme

Gilead Sciences

MundiPharma

Secura Bio

TG Therapeutics

Bayer

Roche

Teva

Eisai

Non-Hodgkin's Lymphoma Drug Segment by Type

Oral

Injection

Non-Hodgkin's Lymphoma Drug Segment by Application

Hospital

Retail Pharmacy

Other

Non-Hodgkin's Lymphoma Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Hodgkin's Lymphoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Hodgkin's Lymphoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Hodgkin's Lymphoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Non-Hodgkin's Lymphoma Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Non-Hodgkin's Lymphoma Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-Hodgkin's Lymphoma Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Major Player Table 3. Injection Major Player Table 4. Global Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Retail Pharmacy Major Player Table 7. Other Major Player Table 8. Non-Hodgkin's Lymphoma Drug Industry Trends Table 9. Non-Hodgkin's Lymphoma Drug Industry Drivers Table 10. Non-Hodgkin's Lymphoma Drug Industry Opportunities and Challenges Table 11. Non-Hodgkin's Lymphoma Drug Industry Restraints Table 12. Global Non-Hodgkin's Lymphoma Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Non-Hodgkin's Lymphoma Drug Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Non-Hodgkin's Lymphoma Drug Market Share by Region (2021-2026) Table 15. Global Non-Hodgkin's Lymphoma Drug Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Non-Hodgkin's Lymphoma Drug Market Share by Region (2027-2032) Table 17. Global Non-Hodgkin's Lymphoma Drug Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Players (2021-2026) Table 19. Global Non-Hodgkin's Lymphoma Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Non-Hodgkin's Lymphoma Drug Key Players Headquarters & Area Served Table 21. Global Non-Hodgkin's Lymphoma Drug Players, Product Type & Application Table 22. Global Non-Hodgkin's Lymphoma Drug Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Non-Hodgkin's Lymphoma Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Non-Hodgkin's Lymphoma Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Type (2021-2026) Table 29. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Type (2027-2032) Table 30. Global Non-Hodgkin's Lymphoma Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Application (2021-2026) Table 34. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Application (2027-2032) Table 35. Acrotech Biopharma Company Information Table 36. Acrotech Biopharma Business Overview Table 37. Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product Portfolio Table 39. Acrotech Biopharma Recent Development Table 40. Eagle Pharmaceuticals Company Information Table 41. Eagle Pharmaceuticals Business Overview Table 42. Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product Portfolio Table 44. Eagle Pharmaceuticals Recent Development Table 45. Epizyme Company Information Table 46. Epizyme Business Overview Table 47. Epizyme Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Epizyme Non-Hodgkin's Lymphoma Drug Product Portfolio Table 49. Epizyme Recent Development Table 50. Gilead Sciences Company Information Table 51. Gilead Sciences Business Overview Table 52. Gilead Sciences Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Gilead Sciences Non-Hodgkin's Lymphoma Drug Product Portfolio Table 54. Gilead Sciences Recent Development Table 55. MundiPharma Company Information Table 56. MundiPharma Business Overview Table 57. MundiPharma Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. MundiPharma Non-Hodgkin's Lymphoma Drug Product Portfolio Table 59. MundiPharma Recent Development Table 60. Secura Bio Company Information Table 61. Secura Bio Business Overview Table 62. Secura Bio Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Secura Bio Non-Hodgkin's Lymphoma Drug Product Portfolio Table 64. Secura Bio Recent Development Table 65. TG Therapeutics Company Information Table 66. TG Therapeutics Business Overview Table 67. TG Therapeutics Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. TG Therapeutics Non-Hodgkin's Lymphoma Drug Product Portfolio Table 69. TG Therapeutics Recent Development Table 70. Bayer Company Information Table 71. Bayer Business Overview Table 72. Bayer Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Bayer Non-Hodgkin's Lymphoma Drug Product Portfolio Table 74. Bayer Recent Development Table 75. Roche Company Information Table 76. Roche Business Overview Table 77. Roche Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Roche Non-Hodgkin's Lymphoma Drug Product Portfolio Table 79. Roche Recent Development Table 80. Teva Company Information Table 81. Teva Business Overview Table 82. Teva Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Teva Non-Hodgkin's Lymphoma Drug Product Portfolio Table 84. Teva Recent Development Table 85. Eisai Company Information Table 86. Eisai Business Overview Table 87. Eisai Non-Hodgkin's Lymphoma Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Eisai Non-Hodgkin's Lymphoma Drug Product Portfolio Table 89. Eisai Recent Development Table 90. North America Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 91. North America Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 92. North America Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 93. North America Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 94. North America Non-Hodgkin's Lymphoma Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Non-Hodgkin's Lymphoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Non-Hodgkin's Lymphoma Drug Revenue by Country (US$ Million) & (2027-2032) Table 97. Europe Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 100. Europe Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 101. Europe Non-Hodgkin's Lymphoma Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe Non-Hodgkin's Lymphoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 103. Europe Non-Hodgkin's Lymphoma Drug Revenue by Country (US$ Million) & (2027-2032) Table 104. China Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 105. China Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 106. China Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 107. China Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 109. Asia Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 110. Asia Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 111. Asia Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Non-Hodgkin's Lymphoma Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Asia Non-Hodgkin's Lymphoma Drug Revenue by Region (US$ Million) & (2021-2026) Table 114. Asia Non-Hodgkin's Lymphoma Drug Revenue by Region (US$ Million) & (2027-2032) Table 115. SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 116. SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 117. SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 118. SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 119. SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Country (US$ Million) & (2027-2032) Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Non-Hodgkin's Lymphoma Drug Image Figure 2. Global Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Hodgkin's Lymphoma Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Image Figure 5. Injection Image Figure 6. Global Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Non-Hodgkin's Lymphoma Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Retail Pharmacy Image Figure 10. Other Image Figure 11. Global Non-Hodgkin's Lymphoma Drug Market Size (US$ Million) & (2021-2032) Figure 12. Global Non-Hodgkin's Lymphoma Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Non-Hodgkin's Lymphoma Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Non-Hodgkin's Lymphoma Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Non-Hodgkin's Lymphoma Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Type (2021-2032) Figure 19. Global Non-Hodgkin's Lymphoma Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Application (2021-2032) Figure 22. North America Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032) Figure 24. North America Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032) Figure 25. North America Non-Hodgkin's Lymphoma Drug Revenue Share by Country (2021-2032) Figure 26. United States Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032) Figure 31. Europe Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032) Figure 32. Europe Non-Hodgkin's Lymphoma Drug Revenue Share by Country (2021-2032) Figure 33. Germany Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032) Figure 43. China Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032) Figure 44. Asia Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032) Figure 46. Asia Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032) Figure 47. Asia Non-Hodgkin's Lymphoma Drug Revenue Share by Region (2021-2032) Figure 48. Japan Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032) Figure 56. SAMEA Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032) Figure 57. SAMEA Non-Hodgkin's Lymphoma Drug Revenue Share by Country (2021-2032) Figure 58. Brazil Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Non-Hodgkin's Lymphoma Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Acrotech Biopharma
  • Eagle Pharmaceuticals
  • Epizyme
  • Gilead Sciences
  • MundiPharma
  • Secura Bio
  • TG Therapeutics
  • Bayer
  • Roche
  • Teva
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Non-Hodgkin's Lymphoma Drug Market by Type
  3. 1.2.1 Global Non-Hodgkin's Lymphoma Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral
  5. 1.2.3 Injection
  6. 1.3 Non-Hodgkin's Lymphoma Drug Market by Application
  7. 1.3.1 Global Non-Hodgkin's Lymphoma Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Retail Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Non-Hodgkin's Lymphoma Drug Market Dynamics
  1. 2.1 Non-Hodgkin's Lymphoma Drug Industry Trends
  2. 2.2 Non-Hodgkin's Lymphoma Drug Industry Drivers
  3. 2.3 Non-Hodgkin's Lymphoma Drug Industry Opportunities and Challenges
  4. 2.4 Non-Hodgkin's Lymphoma Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Non-Hodgkin's Lymphoma Drug Market Perspective (2021-2032)
  2. 3.2 Global Non-Hodgkin's Lymphoma Drug Growth Trends by Region
  3. 3.2.1 Global Non-Hodgkin's Lymphoma Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Non-Hodgkin's Lymphoma Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Non-Hodgkin's Lymphoma Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Non-Hodgkin's Lymphoma Drug Revenue by Players
  2. 4.1.1 Global Non-Hodgkin's Lymphoma Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Non-Hodgkin's Lymphoma Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Non-Hodgkin's Lymphoma Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Non-Hodgkin's Lymphoma Drug Key Players Headquarters & Area Served
  7. 4.4 Global Non-Hodgkin's Lymphoma Drug Players, Product Type & Application
  8. 4.5 Global Non-Hodgkin's Lymphoma Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Non-Hodgkin's Lymphoma Drug Market CR5 and HHI
  11. 4.6.3 2025 Non-Hodgkin's Lymphoma Drug Tier 1, Tier 2, and Tier 3
5 Non-Hodgkin's Lymphoma Drug Market Size by Type
  1. 5.1 Global Non-Hodgkin's Lymphoma Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2032)
  3. 5.3 Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Type (2021-2032)
6 Non-Hodgkin's Lymphoma Drug Market Size by Application
  1. 6.1 Global Non-Hodgkin's Lymphoma Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2032)
  3. 6.3 Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Acrotech Biopharma
  2. 7.1.1 Acrotech Biopharma Company Information
  3. 7.1.2 Acrotech Biopharma Business Overview
  4. 7.1.3 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product Portfolio
  6. 7.1.5 Acrotech Biopharma Recent Developments
  7. 7.2 Eagle Pharmaceuticals
  8. 7.2.1 Eagle Pharmaceuticals Company Information
  9. 7.2.2 Eagle Pharmaceuticals Business Overview
  10. 7.2.3 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product Portfolio
  12. 7.2.5 Eagle Pharmaceuticals Recent Developments
  13. 7.3 Epizyme
  14. 7.3.1 Epizyme Company Information
  15. 7.3.2 Epizyme Business Overview
  16. 7.3.3 Epizyme Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Epizyme Non-Hodgkin's Lymphoma Drug Product Portfolio
  18. 7.3.5 Epizyme Recent Developments
  19. 7.4 Gilead Sciences
  20. 7.4.1 Gilead Sciences Company Information
  21. 7.4.2 Gilead Sciences Business Overview
  22. 7.4.3 Gilead Sciences Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Gilead Sciences Non-Hodgkin's Lymphoma Drug Product Portfolio
  24. 7.4.5 Gilead Sciences Recent Developments
  25. 7.5 MundiPharma
  26. 7.5.1 MundiPharma Company Information
  27. 7.5.2 MundiPharma Business Overview
  28. 7.5.3 MundiPharma Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 MundiPharma Non-Hodgkin's Lymphoma Drug Product Portfolio
  30. 7.5.5 MundiPharma Recent Developments
  31. 7.6 Secura Bio
  32. 7.6.1 Secura Bio Company Information
  33. 7.6.2 Secura Bio Business Overview
  34. 7.6.3 Secura Bio Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Secura Bio Non-Hodgkin's Lymphoma Drug Product Portfolio
  36. 7.6.5 Secura Bio Recent Developments
  37. 7.7 TG Therapeutics
  38. 7.7.1 TG Therapeutics Company Information
  39. 7.7.2 TG Therapeutics Business Overview
  40. 7.7.3 TG Therapeutics Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 TG Therapeutics Non-Hodgkin's Lymphoma Drug Product Portfolio
  42. 7.7.5 TG Therapeutics Recent Developments
  43. 7.8 Bayer
  44. 7.8.1 Bayer Company Information
  45. 7.8.2 Bayer Business Overview
  46. 7.8.3 Bayer Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Bayer Non-Hodgkin's Lymphoma Drug Product Portfolio
  48. 7.8.5 Bayer Recent Developments
  49. 7.9 Roche
  50. 7.9.1 Roche Company Information
  51. 7.9.2 Roche Business Overview
  52. 7.9.3 Roche Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Roche Non-Hodgkin's Lymphoma Drug Product Portfolio
  54. 7.9.5 Roche Recent Developments
  55. 7.10 Teva
  56. 7.10.1 Teva Company Information
  57. 7.10.2 Teva Business Overview
  58. 7.10.3 Teva Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Teva Non-Hodgkin's Lymphoma Drug Product Portfolio
  60. 7.10.5 Teva Recent Developments
  61. 7.11 Eisai
  62. 7.11.1 Eisai Company Information
  63. 7.11.2 Eisai Business Overview
  64. 7.11.3 Eisai Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Eisai Non-Hodgkin's Lymphoma Drug Product Portfolio
  66. 7.11.5 Eisai Recent Developments
8 North America
  1. 8.1 North America Non-Hodgkin's Lymphoma Drug Revenue (2021-2032)
  2. 8.2 North America Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032)
  5. 8.3 North America Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032)
  9. 8.5 North America Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Non-Hodgkin's Lymphoma Drug Revenue by Country
  11. 8.6.1 North America Non-Hodgkin's Lymphoma Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Non-Hodgkin's Lymphoma Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Non-Hodgkin's Lymphoma Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Non-Hodgkin's Lymphoma Drug Revenue (2021-2032)
  2. 9.2 Europe Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Non-Hodgkin's Lymphoma Drug Revenue by Country
  11. 9.6.1 Europe Non-Hodgkin's Lymphoma Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Non-Hodgkin's Lymphoma Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Non-Hodgkin's Lymphoma Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Non-Hodgkin's Lymphoma Drug Revenue (2021-2032)
  2. 10.2 China Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032)
  5. 10.3 China Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032)
  9. 10.5 China Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Non-Hodgkin's Lymphoma Drug Revenue (2021-2032)
  2. 11.2 Asia Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Non-Hodgkin's Lymphoma Drug Revenue by Country
  11. 11.6.1 Asia Non-Hodgkin's Lymphoma Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Non-Hodgkin's Lymphoma Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Non-Hodgkin's Lymphoma Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Non-Hodgkin's Lymphoma Drug Revenue (2021-2032)
  2. 12.2 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Non-Hodgkin's Lymphoma Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Non-Hodgkin's Lymphoma Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Country
  11. 12.6.1 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Non-Hodgkin's Lymphoma Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst